Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2005

View Archived Issues

N-Acetylcysteine shown to decrease craving in hospitalized cocaine addicts

NFPS potentiates the effect of risperidone on glutamatergic transmission

ABT-510 effective against preclinical and clinical hematological malignancies

Ezetimibe improves lipid parameters in HIV-infected subjects with dyslipidemia

A-60444: synergistic combinations and phase I data

Open study finds escitalopram improves depression in perimenopausal women

Preliminary data from phase I/II study of HuMax-CD20 in CLL

Idiotype vaccination may enhance rituximab therapy in non-Hodgkin's lymphoma

New antibiotic for resistant Gram-positive bacteria

Pan-Bcl inhibitor shows preclinical and early clinical activity in patients with CLL

Promising results for GTI-2040 in younger patients with acute myeloid leukemia

Treatment under way in phase II study of HER-2 Protein AutoVac with QS-21

Merck & Co. restructures R&D, reviews pipeline progress

CollaGenex to acquire SansRosa Pharmaceutical Development

Apoxis acquires rights to anticancer compound from Astellas

European phase III study for SNT-MC17 in Friedreich's ataxia

Crucell opens enrollment in phase I study of West Nile virus vaccine

Roche completes four pivotal studies for CERA in renal anemia

Novartis terminates development of NKS-104

Merck begins phase I trial for S. aureus vaccine

Inhibition of PKA and calcineurin protects against seizures

MedImmune completes enrollment in Numax studies

First study describing androstenol's anticonvulsant properties

Cyclacel and Xcyte Therapies to combine companies

CytRx and UMMS sign agreement for obesity and type diabetes targets

Second clinical study for CTCE-0214

Phase IIa trial of PW-4142 completes enrollment

Corgentech and AlgoRx complete merger

Significant bone activity of Acapodene confirmed in ADT patients

Recent patents cover novel treatment options for cancer

Genentech submits sBLA for Avastin in relapsed metastatic colorectal cancer

Norepinephrine reuptake inhibitors for ADHD emerge from Pfizer R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...